Reagents + proteogenomics pure-play. BioLegend (antibodies/reagents) + TotalSeq (multi-omics) + newborn screening installed base. Recurring reagent pull is the moat.
Conviction●○○○○1 of 5
Research target—Snapshot target
Thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap$12.69BSnapshot value
Multi-omics adoption driving reagent demand; newborn screening franchise expansion; proteogenomics integration tailwind.
Reagent commoditization risk; competitive pressure from larger players (Thermo, Danaher); academic budget sensitivity.
needs X/Reddit sentiment sweep
Snapshot · Not reviewed🟡 Mixed · ins-$0.2M · 13F 15+/10- · short↑0.28
Snapshot · Not reviewed